.
MergerLinks Header Logo

New Deal


Announced

ArchiMed to acquire a majority stake in Suanfarma from Intermediate Capital Group.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private Equity

Spain

Majority

Pharmaceuticals

Single Bidder

Private

Acquisition

Friendly

Pending

nutraceutical ingredients

Cross Border

Synopsis

Edit

ArchiMed, an investment firm, agreed to acquire a majority stake in Suanfarma, a manufacturer and distributor of active pharmaceutical and nutraceutical ingredients, from Intermediate Capital Group, an alternative asset manager. Financial terms are not disclosed. “Given the increasing outsourcing of API and nutraceutical services, the new strategic need for better global supply chain control and an exceptional number of complex ingredients coming off patent, we see fantastic opportunities for manufacturing and distribution excellence in this sector. Suanfarma’s management has the experience to manage an aggressive consolidation of the fast-growing markets for APIs and nutraceuticals. They’ve also got that rare level of expertise and industry intelligence to develop a full suite of complex APIs and nutraceuticals at a time when leading pharma companies are looking for one-stop shopping,” André-Michel Ballester, ArchiMed Managing Partner.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US